ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Despite the unprecedent rates of hematological, cytogenetic and molecular responses achieved with the introduction of multiple ABL1-directed tyrosine kinase inhibitors (TKIs), 20–30% of CML patients fail to achieve long-term benefits from these drugs due to the emergence of resistance mechanisms or because of patient compliance issues [3,4,5].